Nab-PTX treatment increases CXCL-10 expression in pancreatic cancer cells leading to reduced secretion of CAF-derived IL-6 subsequently impairing cancer migration and invasion [31]. This evidence concerns the gene CXCL10 and familial pancreatic carcinoma.